[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370312-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370312-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","exploring-birc-family-genes-as-prognostic-biomarkers-and-therapeutic-targets-in-prostate-cancer","Exploring BIRC family genes as prognostic biomarkers and therapeutic targets in prostate cancer","","Baculoviral inhibitor of apoptosis (IAP) Repeat-Containing (BIRC) genes and their oncogenic role in prostate cancer (PCa) remain incompletely defined. The study identifies BIRC5 and BIRC7 as recurrence-associated genes via survival analysis and divides patients into C1 and C2 subtypes. Survival evaluation links BIRC5/BIRC7 and subtype status to adverse prognosis. Single-cell data pinpoint immune-relevant cell types with enriched BIRC family expression, and mechanistic analysis connects differentially expressed genes to cancer- and immunity-related signaling pathways.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/exploring-birc-family-genes-as-prognostic-biomarkers-and-therapeutic-targets-in-prostate-cancer/370312/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/exploring-birc-family-genes-as-prognostic-biomarkers-and-therapeutic-targets-in-prostate-cancer/370312.png","ImageObject",300,407,{"name":42,"@type":43},"Ezra","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-25","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Which BIRC genes are identified as recurrence-associated in prostate cancer?","Question",{"text":63,"@type":64},"BIRC5 and BIRC7 are identified through survival analysis as genes associated with disease recurrence.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How are prostate cancer patients categorized in the analysis?",{"text":68,"@type":64},"Patients are categorized into two subtypes, C1 and C2, based on the expression patterns of BIRC5 and BIRC7.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the relationship between BIRC5/BIRC7 expression and prognosis?",{"text":72,"@type":64},"Higher expression of BIRC5 and BIRC7 independently correlates with an adverse prognosis in prostate cancer.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370312,1790535626,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Analysis  \nExploring BIRC family genes as prognostic biomarkers and therapeutic targets in prostate cancer  \nXiao‑xiang Yu1 · Yi Liu1 · Zeng‑mi Mo1 · Rong‑jiang Luo1 · Wen‑kai Chen1  \nReceived: 18 August 2024 / Accepted: 20 February 2025  \n© The Author(s) 2025 OPEN  \nAbstract  \nThe potential oncogenic role of Baculoviral inhibitor of apoptosis (IAP) Repeat-Containing (BIRC) genes in prostate cancer (PCa) has yet to be fully investigated. Two genes associated with disease recurrence, BIRC5 and BIRC7, were identified through survival analysis, and prostate cancer patients were categorized into two subtypes, C1 and C2, based on these genes. We performed survival analyses to assess the relationship between subtypes and the prognosis of PCa. Singlecell dataset analysis was used to identify specific cell types with enriched expression of BIRC family genes. Our findings show that BIRC5 and BIRC7 exhibit higher expression in PCa tissues compared to non-cancerous tissues. High expression of BIRC5 and BIRC7 independently correlates with an adverse prognosis in PCa. The analysis of mechanisms reveals that the differentially expressed genes impact signaling pathways associated with cancer and immunity. BIRC5/BIRC7 correlate with several immune cells infiltrating levels including T cells and macrophages. Furthermore, our research indicates that elevated expression of BIRC5 is associated with immune infiltration in PCa. These findings highlight the potential of BIRC5/BIRC7 or C1 subtype as prognostic biomarkers, offering new insights into possible targets for the development of therapeutic biomarkers and immunotherapeutic for PCa.  \nKeywords Biomarker · BIRC · Prognosis · Prostate cancer · Bioinformatics analysis · Immune infiltration  \n1 Introduction  \nThe mortality rate of malignant tumors in China surpasses the global average, posing a serious threat to human health. As of 2020, prostate cancer holds the highest incidence rate among male cancers in 112 countries globally. It accounts for about 1.4 million new cases annually, leading to around 375,000 deaths each year. Prostate cancer is the second most common cancer among males in 2020, with a mortality rate ranking fifth [1, 2] . Prostate cancer incidence exhibits considerable variation across regions and ethnic groups. It is most prevalent in Northern and Western Europe, the Caribbean, Australia/New Zealand, North America, and southern Africa, while Asia and North Africa experience comparatively lower rates [3, 4] . In China, the incidence of prostate cancer has markedly risen due to population aging and shifts in lifestyle habits [5, 6]. Consequently, prostate cancer is poised to impose a substantial health burden on men worldwide [2]. Notwithstanding its clinical utility as a biomarker for diagnosing and prognosticating PCa, prostate-specific antigen  \nSupplementary Information The online version contains supplementary material available at [https://doi.org/10.1007/s12672-025-](https://doi.org/10.1007/s12672-025-)[ ](https://doi.org/10.1007/s12672-025-)[02002-7](02002-7.)[.](02002-7.)  \n* Xiao-xiang Yu, [yxx303@sina.com |](yxx303@sina.com |1Department of Urology)[1](yxx303@sina.com |1Department of Urology)[Department of Urology](yxx303@sina.com |1Department of Urology), The 923rd Hospital of Chinese People’s Liberation Army, Nanning 530021, Guangxi, China.  \nDiscover Oncology  \n(2025) 16:240  \n| [https://doi.org/10.1007/s12672-025-02002-7](https://doi.org/10.1007/s12672-025-02002-7)  \n(PSA) exhibits inherent limitations [7] . For instance, it exhibits variations in sensitivity across different ethnic and racial groups and has poor specificity [7–9] . Given these limitations, there is a critical need to identify novel biomarkers that can aid in the diagnosis, development, and recurrence monitoring of PCa.  \nApoptosis inhibitors, known as IAPs and encoded by BIRC genes, play a critical role in conferring apoptosis resistance in various cancer cells [10–15]. These IAP proteins share sig","cbCaivPgxutiXPjz","https://ap.wps.com/l/cbCaivPgxutiXPjz","pdf",10292829,"English","# Abstract\n# Keywords\n# 1 Introduction\n## Prostate cancer burden and need for novel biomarkers\n## Limitations of PSA and motivation for BIRC-focused biomarkers\n## IAP/BIRC biology and NF-κB signaling background\n## Distinct functions within the BIRC family","[{\"question\":\"Which BIRC genes are identified as recurrence-associated in prostate cancer?\",\"answer\":\"BIRC5 and BIRC7 are identified through survival analysis as genes associated with disease recurrence.\"},{\"question\":\"How are prostate cancer patients categorized in the analysis?\",\"answer\":\"Patients are categorized into two subtypes, C1 and C2, based on the expression patterns of BIRC5 and BIRC7.\"},{\"question\":\"What is the relationship between BIRC5/BIRC7 expression and prognosis?\",\"answer\":\"Higher expression of BIRC5 and BIRC7 independently correlates with an adverse prognosis in prostate cancer.\"}]","Exploring BIRC family genes as prognostic biomarkers and therapeutic targets in prostate cancer | PDF",1790187925,48,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1ce9961ba4e1d5bc7e2a42dbe7aff252.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fad85ebbeb14a0b1b604987eae4edf56.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1bc7a985be7ffd7111a7ff905cb6e237.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a1a39ebc4705c6128dfa72fcb3fd4d6c.webp",980,1301]